BioInformant

Your Global Leader in Stem Cell Market Research

Home » induced pluripotent stem cell

Deal-Making within the Induced Pluripotent Stem Cell (iPS Cell) Industry

By

In this post, we explore seven momentous partnerships that have been formed for purposes of strengthening company dominance within the induced pluripotent stem cell (iPS cell or iPSC) industry.  As you’ll discover, a major theme among the “power players” within the iPSC marketplace is non-exclusive agreements with iPS Academia Japan.

These non-exclusive agreements allow companies access to an absolutely critical iPSC patent portfolio by granting access to the patented discoveries of Dr. Shinya Yamanaka, the scientist who invented induced pluripotent stem cells in 2006.

[Read more…]

Induced Pluripotent Stem Cell News Round-Up | July 2015

By

Induced pluripotent stem cells (iPSCs) represent a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. While this trial has since been paused due to safety concerns, it represents a major milestone in clinical progress with iPSCs.

In another recent event that reverberated throughout the stem cell research community, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued February 2015.

Indeed, every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events that occurred in July of 2015.  [Read more…]

Non-Commercial Organizations Supporting the Development of iPSC Therapies

By

In a recent post, we considered commercial entities supporting the development of induced pluripotent stem cell (iPSC) therapies. It is also important to consider the government and academic entities driving forward therapeutic progress with the cell type.

The primary non-commercial institutions working toward this goal are:

  1. RIKEN Center in Kobe, Japan
  2. Kyoto University in Kyoto, Japan
  3. California Institute for Regenerative Medicine (CIRM) in California, USA

Each of these important institutions and their contributions to the development of new iPSC therapies is explored in detail below.
[Read more…]

Induced Pluripotent Stem Cell News Round-Up| June 2015

By

Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015.

Every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events as of June 2015.  [Read more…]

BioInformant's World-Class Clients